Eighteen years of qualification
Audited Supplier
In This Store
For half a century, Grand Shuyang has continuously innovated and developed in the field of blood (Plasma Derived) products, becoming one of China’s leading high-tech enterprises in this industry. It focuses on both domestic and global markets and boasts a modern production base that integrates automation and information technology, covering the entire product chain and ranking among the top in China in terms of production capacity. Grand Shuyang continuously expands its Plasma-derived product pipeline, including:
Human Albumin · Human Immunoglobulin (pH4) Intravenous INJ · Hepatitis B Human Immunoglobulin (pH4) Intravenous INJ · Hepatitis B Human Immunoglobulin · Tetanus Human Immunoglobulin · Rabies Human Immunoglobulin · Human Immunoglobulin for Intramuscular INJ · Histamine Human Immunoglobulin · Human Coagulation Factor IX · Human Fibrinogen and recombinant and cell gene therapy products.
Shuyang has been developing its international market for 20 years and was the first Chinese PDMP manufacturer to successfully export blood products overseas. Currently, 7 of its products are registered and exported to 24 countries across Asia, Eastern Europe, and Central and South America, contributing to consistent sales growth in these regions. In recent years, overseas income has ranked among the top in China.
-GMP approved in China, Turkey, Russia, and the Philippines.
-ISO 9001/14001/45001 approved.
-50+ patents granted.
-National and provincial honors over the years.
Year of Establishment: 1985
Total Assets(USD): More than 99,999,999
Total Number of Staff: more than 1000
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Production Capacity,Buyers' Specifications Accepted,Quality Service
Other Competitive Advantages:
Patents and Copyrights: The ‘preservative-free dual viral inactivation process’ developed and invented independently by the company has obtained a patent certificate issued by the United States Patent and Trademark Office, with Patent No. US006338849B1, a patent certificate issued by IP Australia, with Patent No. 756017, and a patent certificate issued by the State Intellectual Property Office of P. R. China, with Patent No. ZL98112108.X.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight January 2025
